BRCC2 Inhibits Breast Cancer Cell Growth and Metastasis in Vitro and in Vivo Via Downregulating AKT Pathway

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2013 Aug 10

PMID 23928696

Citations 11

Authors

X Li

X Kong

Y Wang

Q Yang

Affiliations

Soon will be listed here.

Abstract

In our previous study, we demonstrated that the BRCC2 (breast cancer cell 2) gene is a proapoptotic molecule that interacts with Bcl-X(L). BRCC2 downregulation is associated with poor disease-free and overall survival in breast cancer. In this study, we aimed to investigate the role of BRCC2 in tumor suppression in breast cancer. In clinical breast cancer samples, we found that BRCC2 expression was significantly downregulated in cancer lesions compared with paired normal breast tissues. By silencing or overexpressing BRCC2 in breast cancer cells, we found that BRCC2 could inhibit cell growth and metastasis in vitro. An in vivo assay showed that BRCC2 not only dramatically inhibited breast cancer cell xenograft formation and growth but also inhibited breast cancer cell metastasis in a lung metastasis model. Moreover, we demonstrated that BRCC2 inhibited breast cancer metastasis via regulation of the Akt pathway. Thus, our study provided evidence that BRCC2 functions as a novel tumor suppressor in breast cancer and may be a potential therapeutic target for breast cancer management.

Citing Articles

More than 2,500 coding genes in the human reference gene set still have unsettled status.

Maquedano M, Cerdan-Velez D, Tress M bioRxiv. 2024; .

PMID: 39713347 PMC: 11661123. DOI: 10.1101/2024.12.05.626965.

RNU12 inhibits gastric cancer progression via sponging miR-575 and targeting BLID.

Wang S, Zou C, Lin X, Hu D, Su Y, He H Sci Rep. 2023; 13(1):7523.

PMID: 37160927 PMC: 10169768. DOI: 10.1038/s41598-023-34539-4.

microRNA Expression Profiling in Young Prostate Cancer Patients.

Valera V, Parra-Medina R, Walter B, Pinto P, Merino M J Cancer. 2020; 11(14):4106-4114.

PMID: 32368293 PMC: 7196262. DOI: 10.7150/jca.37842.

circRNA-AKT1 Sequesters miR-942-5p to Upregulate AKT1 and Promote Cervical Cancer Progression.

Ou R, Mo L, Tang H, Leng S, Zhu H, Zhao L Mol Ther Nucleic Acids. 2020; 20:308-322.

PMID: 32193155 PMC: 7078494. DOI: 10.1016/j.omtn.2020.01.003.

LncRNA PICART1 suppressed non-small cell lung cancer cells proliferation and invasion by targeting AKT1 signaling pathway.

Zhang C, Su C, Song Q, Dong F, Yu S, Huo J Am J Transl Res. 2019; 10(12):4193-4201.

PMID: 30662662 PMC: 6325487.

References

McGowan P, Duffy M . Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol. 2008; 19(9):1566-72. DOI: 10.1093/annonc/mdn180. View

Eichhorn P, Baselga J . HER2 signatures in breast cancer: ready to go to print?. J Clin Oncol. 2010; 28(11):1809-10. DOI: 10.1200/JCO.2009.26.7146. View

Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson D . Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res. 2007; 67(2):818-26. DOI: 10.1158/0008-5472.CAN-06-3307. View

Zhang L, Lee V, Wong A, Kwong D, Zhu Y, Dong S . MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis. 2012; 34(2):454-63. DOI: 10.1093/carcin/bgs346. View

Dillon R, Marcotte R, Hennessy B, Woodgett J, Mills G, Muller W . Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 2009; 69(12):5057-64. PMC: 4151524. DOI: 10.1158/0008-5472.CAN-08-4287. View

Shi G, Ke A, Zhou J, Wang X, Xu Y, Ding Z . CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology. 2010; 52(1):183-96. DOI: 10.1002/hep.23661. View

DILLON R, White D, Muller W . The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene. 2007; 26(9):1338-45. DOI: 10.1038/sj.onc.1210202. View

Wu Z, Wu Q, Yang J, Wang H, Ding X, Yang F . Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008; 122(9):2050-6. DOI: 10.1002/ijc.23337. View

Li X, Kong X, Huo Q, Guo H, Yan S, Yuan C . Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci. 2011; 102(6):1151-7. DOI: 10.1111/j.1349-7006.2011.01919.x. View

10.

Cavalli L, Santos S, Broustas C, Rone J, Kasid U, Haddad B . Assignment of the BLID gene to 11q24.1 by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2008; 186(2):120-1. PMC: 5806604. DOI: 10.1016/j.cancergencyto.2008.06.011. View

11.

Shah F, Shukla S, Shah P, Shukla H, Patel P . Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer. 2009; 46(3):194-202. DOI: 10.4103/0019-509X.52953. View

12.

Broustas C, Gokhale P, Rahman A, Dritschilo A, Ahmad I, Kasid U . BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J Biol Chem. 2004; 279(25):26780-8. DOI: 10.1074/jbc.M400159200. View

13.

Gentile M, Olsen K, Dufmats M, Wingren S . Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: association with poor survival. Br J Cancer. 1999; 80(5-6):843-9. PMC: 2362276. DOI: 10.1038/sj.bjc.6690430. View

14.

Miller L, Smeds J, George J, Vega V, Vergara L, Ploner A . An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102(38):13550-5. PMC: 1197273. DOI: 10.1073/pnas.0506230102. View

15.

Broustas C, Ross J, Yang Q, Sheehan C, Riggins R, Noone A . The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res. 2010; 16(11):2939-48. DOI: 10.1158/1078-0432.CCR-09-2351. View

16.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

17.

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

18.

Liu J, Weiss H, Rychahou P, Jackson L, Evers B, Gao T . Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene. 2008; 28(7):994-1004. PMC: 2921630. DOI: 10.1038/onc.2008.450. View

19.

Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M, Jurisic V . Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract. 2010; 206(4):241-7. DOI: 10.1016/j.prp.2009.12.003. View

20.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View